期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 19, 期 11, 页码 3474-3482出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2011.04.025
关键词
Tyrosinase inhibitors; Dalea elegans; 5,2 ',4 '-Trihydroxy-2 '',2 ''-dimethylchromene-(6,7:5 '',6 '')-flavanone
资金
- Catholic University of Cordoba
- FONCyT [PICT 2005]
- PICTO [CRUP 2005]
- FONCYT PICT-PRH [20 2009]
To aid the pharmaceutical and cosmetic industry in the development of alternatives to prevent melanin-related hyperpigmentation disorders, the plant Dalea elegans was submitted to fractionation with the aim of obtaining its anti-tyrosinase principle. Bioguided fractionation of D. elegans led to the isolation of 5,2',4'-trihydroxy-2 '',2 ''-dimethylchromene-(6,7: 5 '',6 '')-flavanone (1) as the active compound. This novel flavanone, named as dalenin, showed notable activity at inhibiting tyrosinase using L-tyrosine or L-DOPA as substrates with IC50 values of 0.26 and 18.61 mu M, respectively. This meant that the flavanone was 52 and 495 times more effective as a monophenolase inhibitor than hydroquinone and kojic acid, respectively. With L-DOPA as a substrate, compound 1 showed itself 59 times more effective at inhibiting the enzyme than hydroquinone and showed the same level of effectiveness as that of kojic acid. It was found that the flavanone behaved as a reversible inhibitor of the enzyme and that it was a mixed-I type or a non-competitive inhibitor with L-tyrosine or L-DOPA as substrates, respectively. Molecular modeling studies were conducted confirming the inhibitory potency of dalenin and showing that the 2',4'-dihydroxy substituents are important for the interaction with the enzyme. The results suggest that compound 1 has great potential to be further developed as a pharmaceutical and cosmetic agent for use in dermatological disorders associated with melanin. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据